Joseph Dowling

CV Sciences, Inc. (OTCQB:CVSI), a hemp-focused wellness company, announced stable revenue in its Q3 2024 financials on Thursday. The company generated $3.9 million in revenue, a slight decline from $4.1 million in Q3 2023, yet maintained a gross margin of 46%, up from 45.1% the previous year. Q3...

CV Sciences, Inc. (OTCQB:CVSI) a hemp-focused wellness company announced on Tuesday its financial results for the second quarter that ended June 30, 2024, revealing a flat revenue year-over-year at $4 million for the period. "Revenues for our core business remained stable at $4 million in the...

CV Sciences, Inc. (OTCQB:CVSI), a San Diego-based company specializing in hemp extracts, nutraceuticals and plant-based foods announced its financial results Tuesday for the quarter ended March 31, 2024. The company reported a slight decline in its first-quarter revenue, generating $4 million...

Hemp-focused CV Sciences, Inc. (OTCQB:CVSI) announced its financial results on Thursday for the year ended Dec. 31, 2023. The San Diego-based company reported a gross margin of 44.3% for fiscal year 2023, representing an improvement from 34.2% for 2022. For the fourth quarter, its gross margin was...

CV Sciences, Inc. (OTCQB:CVSI) has consummated its purchase of Cultured Foods, a manufacturer and distributor of alternative plant-based vegan foods, the company announced Tuesday.  What Happened The total consideration for the acquisition of Cultured Foods is up to $535,000, consisting of: a cash...

CV Sciences, Inc. (OTCQB: CVSI), a consumer wellness company specializing in hemp extracts and other science-backed, natural ingredients and products, announced its financial results for the quarter ended September 30, 2023. Third Quarter 2023 Financial Highlights Q3 2023 revenue increased to $4.1...

CV Sciences, Inc. (OTCQB: CVSI) reported Monday its financial results for the quarter ended June 30, 2023, disclosing revenue of $4.0 million, compared to $4.1 million for the same period of 2022. "We continue to increase our distribution network in the natural product retail channel. Our...

CV Sciences, Inc. (OTCQB: CVSI) released its financial results today for the first quarter ended March 31, 2023, revealing revenues of $4.1 million for the first quarter of 2023 compared to $4.4 million for the first quarter of 2022 and a sequential increase of 7%. Q1 2023 Financial Results...

CV Sciences, Inc. (OTCQB: CVSI) FY 2022 revenue was $16.2 million, a 19% decrease compared to $20.0 million for 2021. Q4 2022 Financial Highlights Revenue of $3.9 million sequential increase of 3% from $3.8 million in the third quarter 2022, and a decrease of 22% compared to the same prior year...

CV Sciences, Inc. (OTCQB: CVSI) received a formal certificate of grant from the Japan Patent Office for its patent application 7216697. The patent covers methods for treating smokeless tobacco addiction by administering pharmaceutical formulations containing CBD and nicotine. CV Sciences has...

CV Sciences (OTCQB: CVSI) shares were trading 10.69% higher at $0.044 per share at the time of writing Monday morning on company's third-quarter financial results. The company reported Q3 revenue of $3.8 million, a decrease of 27% compared to $5.1 million in Q3 2021. Q3 2022 Highlights Gross...

Hemp CBD manufacturer CV Sciences, Inc. (OTCQB: CVSI) has launched +PlusCBD Reserve Collection softgels to support stress relief and relaxation. This new CBD collection will be available online starting August 15th at $54.99 per 60-count bottle. “It is important to...

CV Sciences, Inc. (OTCQB: CVSI) released its financial results for the quarter ended March 31, 2022, revealing a revenue drop of 8.33% to $4.4 million YoY. First Quarter 2022 and Recent Financial and Operating Highlights Gross margin of 26.0% for first quarter of 2022, compared to 32.4% for the...

CV Sciences, Inc. (OTCQB: CVSI) added +PlusCBD Relief Softgels to its wellness line of CBD products. +PlusCBD Relief Softgels deliver seven times more CBDA and CBD than the original +PlusCBD raw formula and feature Levagen+ PEA, the CBD-like compound shown by clinical studies to be an...

CV Sciences, Inc. (OTCQB: CVSI) is launching +PlusCBD Pain Relief topicals. The San Diego-based supplier and manufacturer of hemp cannabidiol (CBD) products confirmed Tuesday that the new line of topicals consists of four unique over-the-counter products formulated to pinpoint sources of minor pain...